Comparative Pharmacology
Head-to-head clinical analysis: DENTIPATCH versus POLOCAINE MPF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DENTIPATCH versus POLOCAINE MPF.
DENTIPATCH vs POLOCAINE-MPF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic agent that inhibits sodium ion influx into nerve cells, blocking nerve conduction and pain sensation.
Polocaine-MPF (mepivacaine hydrochloride) is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby preventing the initiation and propagation of nerve impulses. This results in reversible loss of sensation in the area of administration.
Apply one 10 mg/10 cm² transdermal patch to intact skin once daily, typically in the morning; remove after 24 hours and replace with a new patch.
Adults: 1-2 cartridges (1.8 mL each) of 2% lidocaine with 1:100,000 epinephrine administered via local infiltration or nerve block, not to exceed 7 mg/kg (maximum 500 mg) for lidocaine.
None Documented
None Documented
Terminal elimination half-life is approximately 7–9 hours; clinically, steady-state is achieved after 2–3 days of daily application.
Terminal elimination half-life: 1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 4-6 hours) and severe renal impairment. Clinical context: short half-life supports continuous infusion for sustained effect.
Approximately 60% of the dose is excreted renally as unchanged drug and metabolites; the remainder is eliminated via biliary/fecal routes.
Renal: >90% as metabolites, primarily 4-hydroxy-2',6'-dimethylacetanilide and pipecoloxylidide; unchanged drug <5%. Biliary/fecal: <5%.
Category C
Category C
Local Anesthetic
Local Anesthetic